Engaging Pattern Recognition Receptors in Solid Tumors to Generate Systemic Antitumor Immunity.

Area of Science:

• Oncology
• Immunology
• Cancer Research

Background:

• Malignant tumors often suppress innate immunity to evade detection.
• Antigen-presenting cells, guided by pathogen recognition receptors (PRRs), are crucial for initiating anti-tumor immunity.
• PRR activation by damage-associated or pathogen-specific signals drives T cell priming, influencing the cancer immunity cycle.

Purpose of the Study:

• To review clinical-stage intratumoral therapies that activate PRRs for anti-tumor immunity.
• To discuss the mechanisms, efficacy, and potential of these PRR-activating strategies in various solid tumors.
• To compare PRR-activating immunotherapies with other treatment modalities and highlight their complementary roles.

Main Methods:

• Discussion of clinical-stage intratumoral modalities targeting PRRs.
• Review of specific PRR agonists (TLR, STING, RIG-I) and microbial agents.
• Analysis of mechanisms of action, clinical data, and requirements for effective in situ immune activation.

Main Results:

• Intratumoral PRR activation can induce Th1-promoting inflammation, crucial for priming CD8+ T cells.
• Endogenous PRR activation, like cGAS-STING, has shown potential in generating spontaneous anti-tumor immunity.
• Various solid tumors, including melanoma and glioblastoma, are contexts for these clinical investigations.

Conclusions:

• Intratumoral PRR activation represents a promising strategy for in situ vaccination, generating personalized anti-tumor responses.
• These approaches have the potential to synergize with existing immunotherapies like immune checkpoint blockade.
• Understanding the nuances of different PRR-activating strategies is key to optimizing anti-tumor efficacy.